General MedicationsTRANSDERMALStandard
SANCUSO
GRANISETRON
Standard Dose
3.1MG/24HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SANCUSO is listed in Drugs@FDA under application 022198 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient GRANISETRON Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 3.1MG/24HR Sponsor CUMBERLAND Submission history Latest submission status date: 2024-09-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview SANCUSO is listed in Drugs@FDA under application 022198 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient GRANISETRON Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 3.1MG/24HR Sponsor CUMBERLAND Submission history Latest submission status date: 2024-09-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.